WO2006000911A1 - Blood and tissue component analysis apparatus - Google Patents
Blood and tissue component analysis apparatus Download PDFInfo
- Publication number
- WO2006000911A1 WO2006000911A1 PCT/IB2005/002051 IB2005002051W WO2006000911A1 WO 2006000911 A1 WO2006000911 A1 WO 2006000911A1 IB 2005002051 W IB2005002051 W IB 2005002051W WO 2006000911 A1 WO2006000911 A1 WO 2006000911A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- blood
- zones
- molecules
- palpabral
- intravascular
- Prior art date
Links
- 239000008280 blood Substances 0.000 title claims abstract description 17
- 210000004369 blood Anatomy 0.000 title claims abstract description 17
- 238000004458 analytical method Methods 0.000 title claims description 8
- 238000000034 method Methods 0.000 claims abstract description 9
- 230000001066 destructive effect Effects 0.000 claims description 6
- 230000005693 optoelectronics Effects 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 5
- 102000001554 Hemoglobins Human genes 0.000 claims description 2
- 108010054147 Hemoglobins Proteins 0.000 claims description 2
- 210000000795 conjunctiva Anatomy 0.000 claims 3
- 238000005375 photometry Methods 0.000 claims 2
- 238000001514 detection method Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 238000005259 measurement Methods 0.000 abstract description 3
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 206010061216 Infarction Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000002572 performance enhancing substance Substances 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000010223 real-time analysis Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
- A61B5/1455—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue using optical sensors, e.g. spectral photometrical oximeters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
- A61B5/14532—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
- A61B5/14546—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue for measuring analytes not otherwise provided for, e.g. ions, cytochromes
Definitions
- Blood and tissue component analysis apparatus Optoelectronic device for measuring molecules present in blood and tissue
- Non-invasive, non-destructive process for qualitative and quantitative analysis of blood and tissue
- Blood formula and composition analysis is routinely performed on patients.
- Today, blood formula composition analysis is invasive and destructive. It is not performed in real time and generally requires the use of costly reagents, high technology equipment and trained laboratory personnel. The sampling of blood and its handling also comports a certain number of risks for both the patient and medical personnel.
- Blood formula analysis yields information pertinent to metabolism as well as the general health and well being of any human or animal.
- the presence or absence of specific molecules in the blood or tissue composition may be an indicator of certain pathology, infection or even a cardiac event such as an infarct us.
- certain molecules need to be monitored for the proper dosing of medication, as in the case of diabetes, where sugar levels need to be measured to optimize administration of insulin.
- Oxygen blood gas levels are commonly measured through oximeters operating on a optoelectronic based apparatus through a process of photon absorption measurement, however non gas components such as sugar, hemoglobin, bilirubin etc., or performance enhancing substances (amphetamines, cocaine, etc.) are still measured through invasive sampling and destructive analysis.
- Current state of the art for the measurement of blood formula therefore implies a time consuming, complex, costly, risky procedure that sometimes, such in the case of a thrombosis, may be delaying treatment for life threatening events.
- the objective of the present invention is overcome the disadvantages of the prior art and offer a new blood formula analysis apparatus, based on a photometric process which is non invasive, non destructive uses no consumable reagents and implies no risk to the patient or the operator and may present immediate results for real time analysis.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Medical Informatics (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Optics & Photonics (AREA)
- Molecular Biology (AREA)
- Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Emergency Medicine (AREA)
- Investigating Or Analysing Materials By Optical Means (AREA)
Abstract
Method and non-invasive apparatus for quantitative and qualitative measurement human/animal components and molecules present in blood and tissue.
Description
Blood and tissue component analysis apparatus Optoelectronic device for measuring molecules present in blood and tissue Non-invasive, non-destructive process for qualitative and quantitative analysis of blood and tissue
Blood formula and composition analysis is routinely performed on patients. Today, blood formula composition analysis is invasive and destructive. It is not performed in real time and generally requires the use of costly reagents, high technology equipment and trained laboratory personnel. The sampling of blood and its handling also comports a certain number of risks for both the patient and medical personnel.
Blood formula analysis yields information pertinent to metabolism as well as the general health and well being of any human or animal. The presence or absence of specific molecules in the blood or tissue composition may be an indicator of certain pathology, infection or even a cardiac event such as an infarct us. In addition, certain molecules need to be monitored for the proper dosing of medication, as in the case of diabetes, where sugar levels need to be measured to optimize administration of insulin.
Oxygen blood gas levels are commonly measured through oximeters operating on a optoelectronic based apparatus through a process of photon absorption measurement, however non gas components such as sugar, hemoglobin, bilirubin etc., or performance enhancing substances (amphetamines, cocaine, etc.) are still measured through invasive sampling and destructive analysis. Current state of the art for the measurement of blood formula therefore implies a time consuming, complex, costly, risky procedure that sometimes, such in the case of a thrombosis, may be delaying treatment for life threatening events.
The objective of the present invention is overcome the disadvantages of the prior art and offer a new blood formula analysis apparatus, based on a photometric process which is non invasive, non destructive uses no consumable reagents and implies no risk to the patient or the operator and may present immediate results for real time analysis.
Claims
Claims
1) A process based on an optoelectronic device which measures molecules present in blood and tissue though a non-destructive non-invasive photometric analysis of the palpabral conjunctiva in vivo. 2) A process based on an optoelectronic device, which detects and measures molecules present in blood though a non-destructive, non-invasive, photometric analysis ex vivo performed through a transparent conduit of the extra corporal circulating blood. 3) A process according to claim 1 above for detecting and measuring strictly intravascular molecules (for example hemoglobin). This, in order to differentiate between extravascular and intravascular zones present in the palpabral conjunctiva allowing for the selection of the zones of measure. 4) A process according to claim 1 above for detecting and measuring strictly extravascular molecules. This, in order to differentiate between extravascular and intravascular zones present in the palpabral conjunctiva allowing for the selection of the zones of measure. 5) An optoelectronic apparatus according to claims 1- 4 above capable of the emission and the detection of photons in the UV, visible, near infrared and far infrared regions. 6) An optoelectronic apparatus according to claim 5 above capable of analysis of the detected photons in comparison with the emitted photon and the subsequent processing of this information in order to yield data on the molecular composition of blood and tissue regions illuminated by the emitted photons.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US58177004P | 2004-06-23 | 2004-06-23 | |
| US60/581,770 | 2004-06-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2006000911A1 true WO2006000911A1 (en) | 2006-01-05 |
Family
ID=35106988
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IB2005/002051 WO2006000911A1 (en) | 2004-06-23 | 2005-06-20 | Blood and tissue component analysis apparatus |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2006000911A1 (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0722692A1 (en) * | 1995-01-20 | 1996-07-24 | Hughes Aircraft Company | Noninvasive method and apparatus for determining body chemistry |
| EP0776628A2 (en) * | 1995-10-31 | 1997-06-04 | Akitoshi Yoshida | Intraocular substance measuring apparatus |
| WO2001016577A1 (en) * | 1999-08-31 | 2001-03-08 | Cme Telemetrix Inc. | Method for determination of analytes using nir, adjacent visible spectrum and discrete nir wavelengths |
-
2005
- 2005-06-20 WO PCT/IB2005/002051 patent/WO2006000911A1/en active Application Filing
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0722692A1 (en) * | 1995-01-20 | 1996-07-24 | Hughes Aircraft Company | Noninvasive method and apparatus for determining body chemistry |
| EP0776628A2 (en) * | 1995-10-31 | 1997-06-04 | Akitoshi Yoshida | Intraocular substance measuring apparatus |
| WO2001016577A1 (en) * | 1999-08-31 | 2001-03-08 | Cme Telemetrix Inc. | Method for determination of analytes using nir, adjacent visible spectrum and discrete nir wavelengths |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12201420B2 (en) | Total hemoglobin screening sensor | |
| US9974451B2 (en) | System and method for a biosensor monitoring and tracking band | |
| US20190167206A1 (en) | System and method for a biosensor integrated in a vehicle | |
| Clarke et al. | A history of blood glucose meters and their role in self-monitoring of diabetes mellitus | |
| US6968221B2 (en) | Low-cost method and apparatus for non-invasively measuring blood glucose levels | |
| EP0944347B1 (en) | Device for noninvasive determination of blood parameters | |
| EP3337390B1 (en) | Health monitoring using a non-invasive, multi-band biosensor | |
| US20040260162A1 (en) | Analysis system for reagent-free determination of the concentration of an analyte in living tissue | |
| US20090054753A1 (en) | Variable Sampling Interval for Blood Analyte Determinations | |
| US10542919B2 (en) | Method and system for non-invasive blood glucose detection utilizing spectral data of one or more components other than glucose | |
| WO1998003847A9 (en) | Device for noninvasive determination of blood parameters | |
| WO1990007905A1 (en) | Non-invasive measurement of blood glucose | |
| US9352054B2 (en) | Method and apparatus for kidney function analysis | |
| WO2003077761A1 (en) | Blood analyzer | |
| Nirupa et al. | Non-invasive measurement of hemoglobin content in blood | |
| JP2009508562A (en) | Medical device | |
| Ogunsanya et al. | Design and development of a non-invasive glucometer system | |
| RU2574000C2 (en) | Method and apparatus for measuring immune and oxygen system and drug screening | |
| WO2006000911A1 (en) | Blood and tissue component analysis apparatus | |
| Fajrin et al. | Development of Diabetes Detection Equipment Using TCS3200 and PH SKU: SEN0161 Sensors | |
| Slingerland et al. | Evaluation of portable blood glucose meters. Problems and recommendations | |
| Isbell et al. | Glucose meters: Where are we now? Where are we heading? | |
| US20240341623A1 (en) | System and method for congestive heart failure biomarker detection | |
| WO2017168432A1 (en) | A non invasive hba1c meter for measuring blood glucose levels in diabetic patients without physical blood sample using nir (near infra red light) | |
| US20240402149A1 (en) | Automated, multi-parameter blood-measuring system |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
| 32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 69(1) EPC, AS PER OUR COMMUNICATION OF 15.05.07 (EPO FORM1205A) |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 05756303 Country of ref document: EP Kind code of ref document: A1 |